-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Protein misfolding is the most striking feature of all common neurodegenerative diseases, each with a distinct but overlapping major protein
.
α-synuclein (α-syn) has been extensively studied as a pathogenic trigger, disease marker, and therapeutic target for synucleinopathies
.
The main diagnostic criteria for Parkinson's disease (PD) rely primarily on the constellation of clinical symptoms, however the neurodegenerative process is thought to begin many years before significant clinical signs are observed
.
Therefore, there is an urgent need to identify high-risk patients
before clinical features emerge.
Identify powerful diagnostic biomarkers that can reflect the clinical course
of Parkinson's disease (PD).
A study published in Neurology today proposes a new approach to study disease-associated α-syn aggregates as biomarkers for clinical staging of PD
.
Seed amplification assay (SAA) and enzyme-linked immunosorbent assay (ELISA) are combined to provide quantitative test readings
that reflect the clinical severity of patients with PD.
To achieve this, the study initially explored the potential of the test using two sets of human cerebrospinal fluid (pilot and validation set), and then validated with two separate cohorts of human cerebrospinal fluid: discovery (62 PD, 34 controls) and validation (49 PD, 48 controls).
The combined testing of SAA and ELISA has been found to be more diagnostic than SAA alone, providing information
on the stage of disease through correlation with clinical measures of disease severity.
This study provides Category III evidence that CSF-tested α-syn oligomers can accurately distinguish patients with Parkinson's disease from normal controls, and that CSF-detected α-syn oligomer levels correlate
with Parkinson's disease severity.
Source: Majbour N, Aasly J, Abdi I, et al.
Disease-Associated α-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage [published online ahead of print, 2022 Sep 12].
Neurology.
2022; 10.
1212/WNL.
0000000000201199.
doi:10.
1212/WNL.
0000000000201199
